Harbinger Research

Harbinger Health is a biotechnology company founded by Flagship Pioneering that is developing a proprietary platform for the early detection of cancer. The company's technology, known as the Harbinger platform (H3), combines high-resolution blood-based epigenetic profiling with advanced machine learning to identify cancer at its earliest, most treatable stages. By focusing on the biological drivers of cancer rather than just late-stage mutations, Harbinger Health aims to provide a low-cost, accessible liquid biopsy solution for pan-cancer screening. The company is currently validating its approach through large-scale clinical studies, including the CORE-HL trial, to enable early intervention and improve patient outcomes across multiple oncology indications.